A Study to Assess the Abuse Potential of Intranasal Cebranopadol

Phase 1

Active, not recruiting

• Conditions: Abuse, Drug
• Interventions: Drug: Cebranopadol- 600 ug; Drug: Cebranopadol- 1000ug; Drug: Treatment C; Drug: Qualification; Drug: Cebranopadol- 800ug; Drug: Treatment B

• Registration Number: NCT06453265
• Lead Sponsor: Tris Pharma, Inc.

Brief Summary

The purpose of this study to Assess the Abuse Potential of Intranasal Cebranopadol Compared to Oxycodone and Placebo in Healthy, Nondependent Recreational Opioid Users.

Detailed Description

This study will be conducted to examine the intranasal abuse potential of cebranopadol compared with oxycodone HCl IR and placebo in recreational opioid users with intranasal experience, a Dose Escalation Phase (Part A) will first be conducted to determine a safe dose for evaluation in the Main Study (Part B).

The Dose Selection Phase (Part A) will consist of 3 phases: Screening, Treatment and Follow-up. Subjects will participate in an outpatient medical screening visit, a 4-day treatment visit and a follow-up phone call.

The Main Study (Part B) will consist of 4 phases: Screening, Qualification, Treatment and Follow-up. Subjects will participate in an outpatient screening visit, a 4-day Qualification Phase, a 30-day Treatment Phase and a follow-up phone call.

Study Timeline

• Study First Submitted: 2024-06-05
• Study First Submitted QC: 2024-06-10
• Study First Posted: 2024-06-11
• Study Start: 2024-06-28
• Primary Completion: 2024-11-06
• Status Verified: 2024-12
• Last Update Submitted: 2024-12-09
• Last Update Posted: 2024-12-13
• Study Completion: 2025-03

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

• Experienced opioid user who meets the following criteria: (1) has used opioids for nontherapeutic purposes (i.e., for psychoactive effects) on at least 10 occasions in the year prior to Screening; (2) has used opioids at least once in the 12 weeks prior to Screening; and (3) self-reported intranasal use of drugs of abuse on at least 3 occasions in the year prior to Screening.
• Subjects must be in good health as determined by medical history, physical examination, 12-lead ECG and vital signs measures (pulse rate, systolic and diastolic blood pressure, respiratory rate and oxygen saturation using pulse oximetry) at Screening.
• Subjects must be willing to comply with the requirements and restrictions of the study.

Key

Exclusion Criteria

• Drug or alcohol dependence in the 12 months prior to Screening (except nicotine), as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR), or any self-reported dependence or "addiction" within the subject's lifetime (except nicotine or caffeine).
• Subjects who have ever been in treatment for substance use disorder(s) (except smoking cessation).
• History or presence of any clinically significant cardiac, psychiatric, endocrine, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, renal or other disease at Screening, which, in the opinion of the investigator, would jeopardize the safety of the subject or the validity of the study results.
• Clinically significant abnormalities in the intranasal cavity (including a deviated septum, perforated nasal septum, rhinorrhea, or excessive sneezing) or any condition that, in the opinion of the investigator, would interfere with the study procedures, data integrity or would compromise the safety of the subject. Subjects with nasal piercings/nose rings will be required to remove them for the duration of their inpatient stay.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Dose Selection- 600ug (Part A)	Cebranopadol- 600 ug	Cebranopadol 600 ug single dose
Dose Selection- 1000 ug (Part A)	Cebranopadol- 1000ug	Cebranopadol 1000 ug single dose
Treatment Phase C (Part B)	Treatment C	- Treatment C: Placebo
Qualification Phase - Placebo (Part B)	Qualification	Matching Placebo
Dose Selection - 800 ug (Part A)	Cebranopadol- 800ug	Cebraopadol 800 ug single dose
Qualification Phase - Oxycodone (Part B)	Qualification	Oxycodone 40mg
Treatment Phase B- (Part B)	Treatment B	- Treatment B: Oxycodone HCl IR 40 mg

Primary Outcome Measures

Name	Time	Method
Drug Liking VAS Emax	48 hrs of Tmax for each treatment	The primary pharmacodynamic endpoint (Drug Liking VAS Emax) will be evaluated with a linear mixed-effects model, containing treatment, period, sequence and first-order carryover as fixed effects and subject nested within sequence as random effect, using the Modified Completer Population

Trial Locations

Locations (1)

Ohio Clinical Trials, Inc.; 🇺🇸 Columbus, Ohio, United States